Department of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey.
Ankara University Cancer Institute, Ankara, Turkey.
JCO Glob Oncol. 2024 Aug;10:e2400201. doi: 10.1200/GO.24.00201.
Durable complete response rates for metastatic renal cell carcinoma (mRCC) and metastatic bladder cancer (mBC) are low despite new therapy. Palliative care focuses on life extension and quality of life (QoL), not cure. This study aims to investigate patients' perceptions of treatment outcomes in mRCC and mBC and to assess the influence of QoL and optimism levels on these perceptions.
From March 15, 2023, to January 15, 2024, a multicenter, cross-sectional online survey was carried out, targeting patients diagnosed with mRCC and mBC. The survey comprised structured questions aimed at evaluating perceptions concerning disease cure, symptom improvement, daily activity performance, and life extension due to treatment. Additionally, to evaluate optimism and QoL, the European Organization for Research and Treatment of Cancer 30.3 QoL questionnaire and life orientation test were implemented. Study on patients' perceptions of treatment outcomes in metastatic kidney and bladder cancer shows high optimism, inaccurate cure beliefs.
In total, 169 patients participated in the survey; the majority of the patients stated their general health status as good (72.2%) and excellent (13.6%). Patients who rated their overall health status as good-excellent had a higher median general QoL and optimism score compared with those who rated it as fair-poor. In all, 85.2% of patients considered the possibility of a cure very likely or likely. Most participants believed treatment could provide symptom relief (30.2% very likely, 49.1% likely), enhanced ability to perform daily activities (28.4% very likely, 55.6% likely), and life extension (32.5% very likely, 53.3% likely). Patients responding very likely and likely to these questions regarding treatment outcomes had higher QoL and optimism scores than those responding a little likely and not possible.
The majority of patients with mRCC and mBC held inaccurate beliefs about treatment outcomes. Better QoL and optimism were associated with increased inaccuracy.
转移性肾细胞癌（mRCC）和转移性膀胱癌（mBC）的持久完全缓解率尽管有新的治疗方法仍很低。姑息治疗侧重于延长生命和提高生活质量（QoL），而不是治愈。本研究旨在调查 mRCC 和 mBC 患者对治疗结果的看法，并评估 QoL 和乐观水平对这些看法的影响。
2023 年 3 月 15 日至 2024 年 1 月 15 日，进行了一项多中心、横断面在线调查，针对 mRCC 和 mBC 患者。该调查包括旨在评估对疾病治愈、症状改善、日常活动能力表现和治疗延长生命的治疗效果的看法的结构化问题。此外，为了评估乐观和 QoL，使用了欧洲癌症研究和治疗组织 30.3 QoL 问卷和生活取向测试。研究表明，转移性肾和膀胱癌患者对治疗结果的看法高度乐观，不准确的治愈信念。
共有 169 名患者参与了调查；大多数患者认为他们的一般健康状况良好（72.2%）和优秀（13.6%）。将总体健康状况评为良好-优秀的患者的中位一般 QoL 和乐观评分高于评为一般-较差的患者。总的来说，85.2%的患者认为治愈的可能性非常大或可能。大多数患者认为治疗可以提供症状缓解（30.2%非常可能，49.1%可能）、增强日常活动能力（28.4%非常可能，55.6%可能）和延长生命（32.5%非常可能，53.3%可能）。对治疗结果非常可能和可能的问题作出回应的患者的 QoL 和乐观评分高于回答可能性较小和不可能的患者。
大多数 mRCC 和 mBC 患者对治疗结果存在不准确的看法。更好的 QoL 和乐观水平与增加的不准确性相关。
